Literature DB >> 20881959

Update on new antivirals under development for the treatment of double-stranded DNA virus infections.

L K Dropulic1, J I Cohen.   

Abstract

All the currently available antiviral agents used in the treatment of double-stranded (ds) DNA viruses, with the exception of interferon-α, inhibit the same target, the viral DNA polymerase. With increasing reports of the development of resistance of herpes simplex virus (HSV), cytomegalovirus (CMV), and hepatitis B virus (HBV) to some of these drugs, new antiviral agents are needed to treat these infections. Additionally, no drugs have been approved to treat several DNA virus infections, including those caused by adenovirus, smallpox, molluscum contagiosum, and BK virus. We report the status of 10 new antiviral drugs for the treatment of dsDNA viruses. CMX-001 has broad activity against dsDNA viruses; 3 helicase-primase inhibitors, maribavir, and FV-100 have activity against certain herpesviruses; ST-246 inhibits poxviruses; GS-9191 inhibits papillomaviruses; and clevudine and emtricitabine are active against HBV. Most of these drugs have completed at least phase I trials in humans, and many are in additional clinical trials.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20881959      PMCID： PMC3426500          DOI： 10.1038/clpt.2010.178

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  59 in total

1.  ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.

Authors:  Koji Chono; Kiyomitsu Katsumata; Toru Kontani; Masayuki Kobayashi; Kenji Sudo; Tomoyuki Yokota; Kenji Konno; Yasuaki Shimizu; Hiroshi Suzuki
Journal:  J Antimicrob Chemother       Date:  2010-06-09       Impact factor: 5.790

2.  Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro.

Authors:  Parmjeet Randhawa; Noush Afarin Farasati; Ron Shapiro; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.

Authors:  W Lawrence Drew; Richard C Miner; Gail I Marousek; Sunwen Chou
Journal:  J Clin Virol       Date:  2006-09-08       Impact factor: 3.168

4.  Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease.

Authors:  Judith Baumeister; Ruediger Fischer; Peter Eckenberg; Kerstin Henninger; Helga Ruebsamen-Waigmann; Gerald Kleymann
Journal:  Antivir Chem Chemother       Date:  2007

5.  High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.

Authors:  Subhajit Biswas; Mihaiela Swift; Hugh J Field
Journal:  Antivir Chem Chemother       Date:  2007

6.  A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

Authors:  Seng Gee Lim; Tay Meng Ng; Nelson Kung; Zahary Krastev; Miroslava Volfova; Petr Husa; Samuel S Lee; Sing Chan; Mitchell L Shiffman; Mary Kay Washington; Amy Rigney; Jane Anderson; Elsa Mondou; Andrea Snow; Jeff Sorbel; Richard Guan; Franck Rousseau
Journal:  Arch Intern Med       Date:  2006-01-09

Review 7.  Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo.

Authors:  Brent E Korba; Phillip A Furman; Michael J Otto
Journal:  Expert Rev Anti Infect Ther       Date:  2006-08       Impact factor: 5.091

8.  Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.

Authors:  Mathew M Adams; Amanda D Rice; R W Moyer
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

9.  Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection.

Authors:  Elena Sbrana; Robert Jordan; Dennis E Hruby; Rosa I Mateo; Shu-Yuan Xiao; Marina Siirin; Patrick C Newman; Amelia P A Travassos DA Rosa; Robert B Tesh
Journal:  Am J Trop Med Hyg       Date:  2007-04       Impact factor: 3.707

10.  Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

Authors:  Debra C Quenelle; Mark N Prichard; Kathy A Keith; Dennis E Hruby; Robert Jordan; George R Painter; Alice Robertson; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.938
View more
  27 in total

Review 1.  BK polyomavirus: emerging pathogen.

Authors:  Shauna M Bennett; Nicole M Broekema; Michael J Imperiale
Journal:  Microbes Infect       Date:  2012-02-24       Impact factor: 2.700

2.  Identification of protein-protein interaction inhibitors targeting vaccinia virus processivity factor for development of antiviral agents.

Authors:  Norbert Schormann; Charnell Inglis Sommers; Mark N Prichard; Kathy A Keith; James W Noah; Manunya Nuth; Robert P Ricciardi; Debasish Chattopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

3.  Detection of molluscum contagiosum virus (MCV) DNA in the plasma of an immunocompromised patient and possible reduction of MCV DNA with CMX-001.

Authors:  Jeffrey I Cohen; Wilmer Davila; Mir A Ali; Siu-Ping Turk; Edward W Cowen; Alexandra F Freeman; Kening Wang
Journal:  J Infect Dis       Date:  2012-01-19       Impact factor: 5.226

Review 4.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.

Authors:  Thomas Stamminger; Nina Reuter; Adriana Svrlanska; Anna Reichel; Eva-Maria Schilling; Myriam Scherer
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

6.  Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.

Authors:  Tracy L Lemonovich; Richard R Watkins
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

7.  The Noninvasive Urinary Polyomavirus Haufen Test Predicts BK Virus Nephropathy in Children After Hematopoietic Cell Transplantation: A Pilot Study.

Authors:  Benjamin L Laskin; Harsharan K Singh; Ulf H Beier; Taylor Moatz; Susan L Furth; Nancy Bunin; David Witte; Jens Goebel; Stella M Davies; Christopher Dandoy; Sonata Jodele; Volker Nickeleit
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

Review 8.  Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges.

Authors:  Charles H Cook; Joanne Trgovcich
Journal:  Antiviral Res       Date:  2011-03-23       Impact factor: 5.970

Review 9.  Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2013-04

Review 10.  Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies.

Authors:  Mackenzie J Dodge; Katelyn M MacNeil; Tanner M Tessier; Jason B Weinberg; Joe S Mymryk
Journal:  Antiviral Res       Date:  2021-02-10       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.